Garth Lees-Rolfe

CIK: 0002017374

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (71.4%)

Compensation grants

Other (G, F, J, C, D, …)2 (28.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

LUDG

LUDWIG ENTERPRISES, INC.

Director

IKT

Inhibikase Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
5.8K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Award(A)
Stock Option (Right to Buy)
Direct
5.8K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
90K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Award(A)
Stock Option (Right to Buy)
Direct
90K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
470.9K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
235.4K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
432.9K shares-

		Type	Shares	Price		Ownership
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	5,834	-	-	Direct
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	5,834	-	-	Direct
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	90,000	-	-	Direct
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	90,000	-	-	Direct
Jan 3, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	470,861	-	-	Direct
Jan 3, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	235,383	-	-	Direct
Jan 3, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	432,853	-	-	Direct

1-7 of 7 transactions

About Lees-Rolfe Garth

Lees-Rolfe Garth (SEC CIK 0002017374) files insider reports with the SEC as Director of LUDWIG ENTERPRISES, INC. (LUDG) and Chief Financial Officer of Inhibikase Therapeutics, Inc. (IKT).

Signal8 holds 3 ownership filings by Lees-Rolfe Garth (1 Form 3, 2 Form 4), filed between Jan 7, 2025 and Jun 26, 2025. Those filings report 7 transactions, from Jan 3, 2025 to Jan 21, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Lees-Rolfe Garth's filings is in LEXINGTON, MA.

Recent filings by Lees-Rolfe Garth

Jan 21, 2025: Disposition to issuer transaction of IKT derivative securities (Form 4, code D).
Jan 21, 2025: Grant or award of IKT derivative securities (Form 4, code A).
Jan 21, 2025: Disposition to issuer transaction of IKT derivative securities (Form 4, code D).
Jan 21, 2025: Grant or award of IKT derivative securities (Form 4, code A).
Jan 3, 2025: Grants or awards of IKT derivative securities (3 lines, Form 4, code A).

Other insiders filing for LUDWIG ENTERPRISES, INC. (LUDG)

FOXO TECHNOLOGIES INC., 10% Owner
HAUSMAN MARVIN S MD, 10% Owner
Todd Charles T Jr, CHIEF EXECUTIVE OFFICER

How to read Form 4 transaction codes